Streetbeat News

Analyst Ratings

CRSP

RBC Capital analyst Luca Issi maintains a Sector Perform rating on CRISPR Therapeutics (NASDAQ:CRSP) but lowers the price target from $66 to $60.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:56 pm

ONIT

Keefe, Bruyette & Woods analyst Bose George maintains an Outperform rating on Onity Group (NYSE:ONIT) and raises the price target from $33 to $35.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:55 pm

CSX

RBC Capital analyst Walter Spracklin has reiterated a Sector Perform rating on CSX (NASDAQ:CSX) and maintained a $36 price target.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:54 pm

BCRX

Barclays analyst Gena Wang maintains an Equal-Weight rating on BioCryst Pharma (NASDAQ:BCRX) and raises the price target from $6 to $7.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:53 pm

DSGN

RBC Capital analyst Leonid Timashev has reiterated a Sector Perform rating on Design Therapeutics (NASDAQ:DSGN) and maintained a $4 price target.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:52 pm

TBPH

Leerink Partners has downgraded Theravance Biopharma (NASDAQ:TBPH) from Outperform to Market Perform and lowered the price target from $15 to $10.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:51 pm

PAG

JP Morgan analyst Rajat Gupta maintains an Underweight rating on Penske Automotive Group (NYSE:PAG) but raises the price target from $135 to $140.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:48 pm

ARGX

CRWD

LION

LUMN

SAH

Top Wall Street analysts have upgraded their ratings for several companies, including CrowdStrike Holdings, Lionsgate Studios, Lumen Technologies, Sonic Automotive, and argenx SE. These upgrades reflect a positive outlook for these companies despite some mixed price target adjustments.

Portfolio Pulse from Avi Kapoor

August 06, 2024 | 12:48 pm

EBAY

Truist Securities has maintained its Hold rating on eBay (NASDAQ:EBAY) while raising the price target from $50 to $58.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:48 pm

NUVB

RBC Capital analyst Gregory Renza has reiterated an Outperform rating on Nuvation Bio (NYSE:NUVB) and maintained a $5 price target.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:48 pm